Carillion looks to sell its UK Healthcare arm

By Catherine Sturman
Construction giant Carillion has been struggling for some time, yet this is set to change. With losses of over £1 billion in just six months, the compa...

Construction giant Carillion has been struggling for some time, yet this is set to change. With losses of over £1 billion in just six months, the company has been rumoured to be selling off its UK healthcare business after increased interest from potential investors who view its long-term potential.

At present, the company is a leader in facilities management for the National Health Service, leading to a large number of proposals from potential investors. It has been stated that the company aims to receive over £300 million for a potential sale.

Related stories

“The Board of Carillion confirms that, consistent with Carillion’s announcement on 29 September 2017, it has received proposals from more than one credible counterparty for a possible acquisition of that business,” the company said.

“A further announcement will be made as and when appropriate.”

At present, the company is removing itself from all public-private partnership deals, but is continuing to work on the development of hospital facilities globally. However, staff shortages are responsible for ongoing delays to such construction works.

Share

Featured Articles

Healthcare Business roundup: Baxter, Sanofi & Eli Lilly

Baxter International to sell kidney care spin-off Vantive; Sanofi's consumer health unit ‘to be separated’; Eli Lilly to buy Morphic Holding for $3.2bn

Trane Technologies Helping US Hospitals Meet Climate Pledge

Christy Fetsch of Trane Technologies explains how the company is helping US hospitals meet White House sustainability pledges for US healthcare provision

Nestlé Health Science Targets Weight Loss Side-Effects

Nestlé Health Science launches nutrition initiative to counteract side effects of weight-loss drugs, including hollowed-out 'Ozempic Face'

Eli Lilly Alzheimer's Drug Kisunla Approved in US by FDA

Medical Devices & Pharma

WEF: Gender Health Gap 'Costs women 75mn years of Life'

Medical Devices & Pharma

Schneider: Swathe of NHS Failing to Measure Sustainability

Sustainability